Key result
This review discusses the pathophysiologic links between depression and cardiovascular disease progression and the potential benefits of anti-depressants in patients with coronary disease.
Why the study?
Does pharmacologic treatment of depression improve cardiovascular outcomes in patients with myocardial infarction?
Does pharmacologic treatment of depression improve cardiovascular outcomes in patients with myocardial infarction?
This review highlights the pathophysiologic links between depression and cardiovascular disease progression, and explores the safety and efficacy of antidepressants in patients with coronary disease.
Antidepressants in coronary disease warrant further study; leaves open whether they improve cardiovascular outcomes post-MI.
Depression is a common medical problem and is more prevalent among patients with coronary artery disease. Whether early detection and treatment of depression will enhance cardiovascular outcome is uncertain. Obviously, the safety and efficacy of the anti-depression drugs is an important link. This article reviews the patho-physiologic and behavioural links between depression and cardiovascular disease progression, the treatment of depression, and the potential benefits of anti-depressants in patients with coronary disease.
No takes yet. Share an insight, caveat, or question.
Jeong-Hoon et al. (2011) conducted a review in Depression and myocardial infarction. Anti-depressants was evaluated. This review discusses the pathophysiologic links between depression and cardiovascular disease progression and the potential benefits of anti-depressants in patients with coronary disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: